SCHEMBL317997

SCHEMBL317997

C=CCc1ccc(O)c(OC)c1NC(C)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.55
GABRA1 P14867 5/20 0.43
GABRB2 P47870 5/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRA2 P47869 1/20 0.43
KDM4E B2RXH2 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
IDO1 P14902 1/20 0.42
ALDH1A1 P00352 2/20 0.40
HSD17B10 Q99714 1/20 0.40
ALOX5 P09917 4/20 0.39
CYP3A4 P08684 1/20 0.39
AR P10275 1/20 0.39
PTGS1 P23219 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
CNR2 P34972 1/20 0.37
PTPN1 P18031 2/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL530900 0.78 ALOX5 (0.42) GABRA1GABRB2KDM4EALDH1A1ALOX5
Acetic Acid SCHEMBL1657269 0.78 PTGS1 (0.44) TRPV1GABRA1GABRB2KDM4EALDH1A1
SCHEMBL2843447 0.77 ALOX5 (0.46) GABRA1GABRB2GABRA5GABRA3GABRA2
Acetic Acid SCHEMBL28484580 0.77 ALOX5 (0.41) GABRA1GABRB2KDM4EALDH1A1ALOX5
SCHEMBL310587 0.77 ALOX5 (0.49) GABRA1GABRB2GABRA5GABRA3GABRA2
SCHEMBL9279198 0.76 HSD17B10 (0.53) GABRA1GABRB2GABRA5GABRA3GABRA2
SCHEMBL28373317 0.75 GABRA1 (0.44) TRPV1GABRA1GABRB2ALDH1A1ALOX5
SCHEMBL1173287 0.75 ALOX5 (0.44) GABRA1GABRB2ALDH1A1ALOX5CYP3A4
SCHEMBL132917 0.74 ALOX5 (0.46) GABRA1GABRB2KDM4EALDH1A1ALOX5
SCHEMBL1869397 0.74 ALOX5 (0.46) GABRA1GABRB2KDM4EALDH1A1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240099995-A1 METHOD OF PREPARING A TOPICAL PHARMACEUTICAL COMPOSITION PHEBRA PTY LTD (AU) 2024-03-28 US claimed
EP-4291171-A1 METHOD OF PREPARING A TOPICAL PHARMACEUTICAL COMPOSITION Phebra Pty Ltd (AU) 2023-12-20 EP claimed
WO-2006127024-A1 REAGENTS AND METHODS FOR LABELING TERMINAL OLEFINS EISAI CO. LTD. (JP) 2006-11-30 WO claimed
US-20060045846-A1 Reagents and methods for labeling terminal olefins EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-03-02 US claimed
US-20050152957-A1 Compositions and delivery systems for administration of a local anesthetic agent CORIUM INTERNATIONAL (US) 2005-07-14 US claimed
US-20030027833-A1 Compositions and delivery systems for administration of a local anesthetic agent CORIUM INTERNATIONAL, INC. 2003-02-06 US claimed
WO-2002089849-A1 COMPOSITIONS AND DELIVERY SYSTEMS FOR ADMINISTRATION OF A LOCAL ANESTHETIC AGENT CORIUM INTERNATIONAL (US) 2002-11-14 WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-4736898-A2 NANOFIBER-HYDROGEL COMPOSITES FOR ENHANCED SOFT TISSUE REPLACEMENT AND REGENERATION The Johns Hopkins University (US) 2026-05-06 EP disclosed
US-20260102540-A1 NANOFIBER-HYDROGEL COMPOSITES AND METHODS FOR INHIBITING ADHESION FORMATION UNIV JOHNS HOPKINS (US) 2026-04-16 US disclosed
US-12544489-B2 Fiber-hydrogel composite surgical meshes for tissue repair THE JOHNS HOPKINS UNIVERSITY (US) 2026-02-10 US disclosed
EP-3790601-B1 NANOFIBER-HYDROGEL COMPOSITES FOR ENHANCED SOFT TISSUE REPLACEMENT AND REGENERATION UNIV JOHNS HOPKINS (US) 2025-12-10 EP disclosed
US-12458731-B2 Mesenchymal cell-binding composite material for tissue restoration THE JOHNS HOPKINS UNIVERSITY (US) 2025-11-04 US disclosed
US-6024976-A TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH NOVEN PHARMACEUTICALS, INC. (US) 2000-02-15 US disclosed
WO-1999015210-A2 BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS NOVEN PHARMACEUTICALS, INC. (US) 1999-04-01 WO disclosed
US-5719197-A DRUG DELIVERY NOVEN PHARMACEUTICALS, INC. (US) 1998-02-17 US disclosed
US-5656286-A BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE NOVEN PHARMACEUTICALS, INC. (US) 1997-08-12 US disclosed
WO-1996040086-A2 COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS NOVEN PHARMACEUTICALS, INC. (US) 1996-12-19 WO disclosed
US-5446070-A Flexible, finite, bioadhesive, therapeutical agent in solid form NOVER PHARMACEUTICALS, INC. (US) 1995-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060045846-A1 Reagents and methods for labeling terminal olefins EEF2, RNF168, REL TRPV1 4296/4885GABRA1 1206/4885GABRB2 2152/4885
US-20260102540-A1 NANOFIBER-HYDROGEL COMPOSITES AND METHODS FOR INHIBITING ADHESION FORMATION NGF, CNTN1, PRPH TRPV1 3646/4885GABRA1 3876/4885GABRB2 3404/4885
US-12544489-B2 Fiber-hydrogel composite surgical meshes for tissue repair CD44, FGB, ILK TRPV1 3749/4885GABRA1 2888/4885GABRB2 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.